These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31534548)

  • 1. Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma.
    Wang QS; Gao LN; Zhu XN; Zhang Y; Zhang CN; Xu D; Cui YL
    Theranostics; 2019; 9(21):6239-6255. PubMed ID: 31534548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycyrrhizin Conjugated Dendrimer and Multi-Walled Carbon Nanotubes for Liver Specific Delivery of Doxorubicin.
    Chopdey PK; Tekade RK; Mehra NK; Mody N; Jain NK
    J Nanosci Nanotechnol; 2015 Feb; 15(2):1088-100. PubMed ID: 26353617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
    Chen D; Pan X; Xie F; Lu Y; Zou H; Yin C; Zhang Y; Gao J
    Int J Nanomedicine; 2018; 13():6855-6870. PubMed ID: 30498347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice.
    Wang C; Li Y; Chen B; Zou M
    Colloids Surf B Biointerfaces; 2016 Oct; 146():31-8. PubMed ID: 27244048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of a Self-Assembled Rhein-Doxorubicin Nanogel Targeting Mitochondria and Investigation on Its Antihepatoma Activity.
    Wu L; Shi Y; Ni Z; Yu T; Chen Z
    Mol Pharm; 2022 Jan; 19(1):35-50. PubMed ID: 34890210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.
    Garg M; Madan J; Pandey RS; Sardana S; Katyal A; Chandra R
    Anticancer Drugs; 2012 Sep; 23(8):836-45. PubMed ID: 22407250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multilayer micro-dispersing system as oral carriers for co-delivery of doxorubicin hydrochloride and P-gp inhibitor.
    Feng C; Li J; Mu Y; Kong M; Li Y; Raja MA; Cheng XJ; Liu Y; Chen XG
    Int J Biol Macromol; 2017 Jan; 94(Pt A):170-180. PubMed ID: 27720963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
    Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
    Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
    Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
    ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of a dual cored hepatoma-specific star glycopolymer nanogel via arm-first ATRP approach.
    Lou S; Zhang X; Zhang M; Ji S; Wang W; Zhang J; Li C; Kong D
    Int J Nanomedicine; 2017; 12():3653-3664. PubMed ID: 28553105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
    Zhang X; Li J; Yan M
    Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Abo Mansour HE; El-Batsh MM; Badawy NS; Mehanna ET; Mesbah NM; Abo-Elmatty DM
    Hum Exp Toxicol; 2020 Nov; 39(11):1528-1544. PubMed ID: 32519553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma.
    Shi L; Tang C; Yin C
    Biomaterials; 2012 Oct; 33(30):7594-604. PubMed ID: 22796165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver cancer cells: targeting and prolonged-release drug carriers consisting of mesoporous silica nanoparticles and alginate microspheres.
    Liao YT; Liu CH; Yu J; Wu KC
    Int J Nanomedicine; 2014; 9():2767-78. PubMed ID: 24940057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer.
    Chang JE; Yoon IS; Sun PL; Yi E; Jheon S; Shim CK
    J Photochem Photobiol B; 2014 Nov; 140():49-56. PubMed ID: 25090224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
    Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
    Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.